Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Hahnen, E; Hauke, J; Gelmon, K; Marmé, F; Ernst, C; Martin, M; Untch, M; Bonnefoi, H; Knudsen, E; Im, SA; DeMichele, A; Van't Veer, L; Kim, SB; Bear, H; McCarthy, N; Rhiem, K; Turner, N; Witkiewicz, A; Rojo, F; Filipits, M; Martin, LA; Fasching, PA; Schem, C; Becker, K; García-Sáenz, JA; Kelly, CM; Reimer, T; Toi, M; Rugo, HS; Denkert, C; Gnant, M; Makris, A; Liu, Y; Valota, O; Felder, B; Weber, K; Nekljudova, V; Loibl, S.

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor plus /Human Epidermal Growth Factor Receptor 2-Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis

Jco Precision Oncology. 2025; 9: Nº de citas: 3 [doi:10.1200/PO-24-00742]

Harbeck, N; Dieras, V; Gelmon, KA; Finn, RS; Martin, M; Neven, P; Kim, S; Ma, J; Gauthier, E; Broughton, E; Doan, J; Rugo, HS.

Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial

Esmo Open. 2025; 10(4): Nº de citas: 3 [doi:10.1016/j.esmoop.2025.104497]

Giannatempo, P; Machiels, JP; Sassa, N; Arranz, JA; Fujii, Y; Su, WP; Keam, B; Culine, S; Shen, YC; Langa, JM; Sarid, D; Aarts, M; Calabro, F; Rosenbaum, E; Moreno, BH; Bavle, A; Xu, JZ; Rha, SY.

Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials

CLINICAL GENITOURINARY CANCER. 2025; 23(2): Nº de citas: 1 [doi:10.1016/j.clgc.2024.102273]

Koshkin VS; Danchaivijitr P; Bae WK; Semenov A; Ozyilkan O; Su YL; Arranz Arija JA; Tsujihata M; Bögemann M; Hendriks MP; Delgado SN; Rosenbaum E; Lopez KA; Bavle A; Liu CC; Imai K; Furka A.

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.

EUROPEAN UROLOGY. 2025; 87(4): 390-395 Nº de citas: 2 [doi:10.1016/j.eururo.2024.11.012]

Moreno, F; Iranzo, V; Alvarez, I; Antón, A; Chacón, JI; Gavilá, J; Martín, M; Rovira, PS; Gratal, P; González, MJF; López, R.

CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : Nº de citas: 1 [doi:10.1007/s12094-025-03896-z]

Kalinsky, K; Bianchini, G; Hamilton, E; Graff, SL; Park, KH; Jeselsohn, R; Demirci, U; Martin, M; Layman, RM; Hurvitz, SA; Sammons, S; Kaufman, PA; Muñoz, M; Lai, J; Knoderer, H; Sandoval, C; Chawla, AR; Nguyen, B; Zhou, YH; Ravenberg, E; Litchfield, LM; Smyth, L; Wander, SA.

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(9): Nº de citas: 43 [doi:10.1200/JCO-24-02086]

García-Alfonso, P; Valladares-Ayerbes, M; Martín, AJM; Herrero, RM; Muñoz, EG; Prat-Llorens, G.

State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives

EXPERT OPINION ON BIOLOGICAL THERAPY. 2025; 25(4): 413-423 Nº de citas: 1 [doi:10.1080/14712598.2025.2477192]

Sobrero, A; Dasari, A; Aquino, J; Lonardi, S; Garcia-Carbonero, R; Elez, E; Yoshino, T; Yao, J; Garcia-Alfonso, P; Kocsis, J; Gracian, AC; Sartore-Bianchi, A; Satoh, T; Randrian, V; Tomasek, J; Chong, GF; Price, T; Yu, ZJ; Geiger, A; Chen, L; Yang, Z; Schelman, WR; Kania, M; Tabernero, J; Eng, C.

Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study

EUROPEAN JOURNAL OF CANCER. 2025; 218: Nº de citas: 5 [doi:10.1016/j.ejca.2025.115268]

Long, GV; Larkin, J; Schadendorf, D; Grob, JJ; Lao, CD; Márquez-Rodas, I; Wagstaff, J; Lebbe, C; Pigozzo, J; Robert, C; Ascierto, PA; Atkinson, V; Postow, MA; Atkins, MB; Sznol, M; Callahan, MK; Topalian, SL; Sosman, JA; Kotapati, S; Thakkar, PK; Ritchings, C; Benito, MP; Re, S; Soleymani, S; Hodi, FS.

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma

JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(8): Nº de citas: 10 [doi:10.1200/JCO.24.00400]

Macarulla, T; Muñoz, A; de Castro, EM; Castillo, A; Cano, MT; Castet, F; Vidal, R; Ferrández, A; Ghanem, I; Ales, I; Vera, R; Lobo, M; Adeva, J; Melian, M; Gallego, I; Laquente, B; Montes, AF; Peinado, P; Paredes, BG; Pazo, R; Escobar, IG; de Mena, IR; Carrato, A; Aranda, E.

Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry

Esmo Real World Data And Digital Oncology. 2025; 7: 100116-100116 Nº de citas: 1 [doi:10.1016/j.esmorw.2025.100116]

Hecht, JR; Oberoi, A; Cabanas, EG; Chon, HJ; Digklia, A; Rottey, S; Jimenez, MM; Chaney, M; Hippenmeyer, J; Lawrence, T; Liu, KT; Hamidi, A; Chesney, J.

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

ONCOLOGIST. 2025; 30(3): Nº de citas: 5 [doi:10.1093/oncolo/oyae203]

Jara, P; De Pace, LA; Piña, IB; Carballeira, CC; Buznego, LA; Ferré, AD.

Recurrence rate and quality of life in women with borderline ovarian tumours, according to surgical approach

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY. 2025; 306: 125-131 [doi:10.1016/j.ejogrb.2025.01.016]

Donia, M; Jespersen, H; Jalving, M; Lee, R; Eriksson, H; Hoeller, C; Hernberg, M; Gavrilova, I; Kandolf, L; Liszkay, G; Helgadottir, H; Zhukavets, A; Pianova, D; Marquez-Rodas, I; Neyns, B; Westgeest, H; Pourmir, I; Sobczuk, P; Ellebaek, E; Amaral, T.

Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028

Esmo Open. 2025; 10(3): Nº de citas: 7 [doi:10.1016/j.esmoop.2025.104295]

Eng, C; Dasari, A; Lonardi, S; Garcia-Carbonero, R; Elez, E; Yoshino, T; Sobrero, A; Yao, JM; Garcia-Alfonso, P; Kocsis, J; Gracian, AC; Sartore-Bianchi, A; Satoh, T; Randrian, V; Tomasek, J; Chong, GF; Yang, Z; Guevara, F; Schelman, W; Pallai, R; Tabernero, J.

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2

ONCOLOGIST. 2025; 30(3): Nº de citas: 7 [doi:10.1093/oncolo/oyae360]

Mukhtar, RA; Gottipati, S; Yau, C; López-Tarruella, S; Earl, H; Hayward, L; Hiller, L; Osdoit, M; van der Noordaa, M; de Croze, D; Hamy, AS; Lae, M; Reyal, F; Sonke, GS; Steenbruggen, TG; van Seijen, M; Wesseling, J; Martín, M; del Monte-Millán, M; Boughey, JC; Goetz, MP; Hoskin, T; Valero, V; Edge, SB; Abraham, JE; Bartlett, JMS; Caldas, C; Dunn, J; Provenzano, E; Sammut, SJ; Thomas, JS; Graham, A; Hall, P; Mackintosh, L; Fan, F; Godwin, AK; Schwensen, K; Sharma, P; Demichele, AM; Cole, K; Pusztai, L; Kim, MO; van 't Veer, L; Cameron, D; Esserman, LJ; Symmans, WF.

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer

Npj Breast Cancer. 2025; 11(1): Nº de citas: 4 [doi:10.1038/s41523-025-00720-3]

Denkert C; Rachakonda S; Karn T; Weber K; Martin M; Marmé F; Untch M; Bonnefoi H; Kim SB; Seiler S; Bear HD; Witkiewicz AK; Im SA; DeMichele A; Pehl A; Van't Veer L; McCarthy N; Stiewe T; Jank P; Gelmon KA; García-Sáenz JA; Westhoff CC; Kelly CM; Reimer T; Felder B; Olivé MM; Knudsen ES; Turner N; Rojo F; Schmitt WD; Fasching PA; Teply-Szymanski J; Zhang Z; Toi M; Rugo HS; Gnant M; Makris A; Holtschmidt J; Nekljudova V; Loibl S.

Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.

CANCER CELL. 2025; 43(2): Nº de citas: 12 [doi:10.1016/j.ccell.2025.01.002]

Peña-Enríquez, R; Bermejo, B; Pollán, M; Díaz-Chacón, A; Gilarranz, YJ; Lorenzo, JJP; Aramburo, AF; de Ibargüen, BCS; Bertrán, AS; Galve-Calvo, E; Jiménez-Arranz, A; Fernández, Y; Pérez, ME; de la Cruz, S; Anton-Torres, A; Moreno, F; Vidal-Losada, MJ; López-Ceballos, MH; Blancas, I; Echarri, MJ; Rincón, R; Caballero, R; Guerrero-Zotano, A; Guil-Luna, S; de la Haba-Rodríguez, J.

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study

Npj Breast Cancer. 2025; 11(1): Nº de citas: 8 [doi:10.1038/s41523-025-00718-x]

Serrano, C; Arregui, M; Carrasco, I; Hindi, N; Martínez-Trufero, J; Martínez-García, J; Molina, A; Paisán, A; Sánchez, R; Sala, MA.

SEOM-GEIS Spanish clinical guidelines for the management of soft-tissue sarcomas (2024)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; 27(4): 1460-1471 [doi:10.1007/s12094-024-03842-5]